v3.26.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net loss $ (2,600,262) $ (3,959,440)  
Adjustments to reconcile net loss to net cash used in operating activities:      
Change in fair value of financial instruments (143,040) 1,399,491  
Gain on extinguishment of financial liabilities (367,809) 0  
Credit loss expense 355,794 120,919  
Depreciation and amortization 646,619 647,037  
Stock-based compensation 441,306 392,106  
Amortization of right-of-use assets 2,423 20,524  
Changes in operating assets and liabilities:      
Accounts receivable (506,119) (255,130)  
Due from related party (8,333) 242,500  
Prepaids and other current assets (237,388) (83,168)  
Accounts payable and accrued liabilities (155,059) 692,586  
Deferred revenue 122,100 358,860  
Operating lease liabilities (2,423) (16,778)  
Net cash used in operating activities (2,452,191) (440,493)  
CASH FLOWS FROM INVESTING ACTIVITIES:      
Purchases of fixed assets (26,752) (11,873)  
Purchase of long-term investments (100,000) 0  
Net cash used in investing activities (126,752) (11,873)  
CASH FLOWS FROM FINANCING ACTIVITIES:      
Repayment of notes payable (528,405) 0  
Payment to shareholder 0 (10,000)  
Proceeds from issuance of common stock 0 90,634  
Proceeds from notes issued during the period 176,750 509,366  
Proceeds from pre-funded warrants, net of issuance costs 514 0  
Payments on factoring payable 0 (28,627)  
Payments on financing lease liability (591,118) (25,000)  
Payments on Encompass Purchase Liability (50,000) 0  
Payments on line of credit (348,952) 0  
Net cash (used in) provided by financing activities (1,341,211) 536,373  
NET CHANGE IN CASH (3,920,154) 84,007  
Cash, Beginning of the period 5,266,286 326,115 $ 326,115
CASH, END OF THE PERIOD 1,346,132 410,122 $ 5,266,286
Supplemental disclosure of cash flow information:      
Cash paid for interest expense 212,476 110,205  
Non-cash investing and financing activities:      
Common stock issued on the exercise of pre-funded warrants 514 0  
Common stock issued on conversion of notes payable 299,345 0  
Common stock issued to settle directors compensation payable 60,762 0  
Common stock issued to settle executives compensation payable 107,902 0  
Common stock issued to settle employees and consultants compensation payable 776,842 0  
Common stock issued as consideration for investment in GoMyRX Inc. 649,800 0  
Common and preferred stock issued to settle accounts payable $ 1,573,800 $ 0